Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

04273

Sigma-Aldrich

Fosfato de sodio dibasic dodecahydrate

meets analytical specification of Ph. Eur., BP, E339, 98.5-102.5% (T)

Sinónimos:

Fosfato de sec-sodio, Fosfato de disodio, Hidrogenofosfato de disodio dodecahydrate

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula lineal:
Na2HPO4 · 12H2O
Número de CAS:
10039-32-4
Peso molecular:
358.14
EC Number:
231-448-7
MDL number:
MFCD00149181
UNSPSC Code:
12161700
PubChem Substance ID:
329747907
NACRES:
NA.25

agency

meets analytical specifications of BP
meets analytical specifications of Ph. Eur.

assay

98.5-102.5% (T)

form

crystals

quality

meets analytical specification of Ph. Eur., BP, E339

impurities

reducing matter, complies
 residual solvents, complies
≤0.001% heavy metals (as Pb)
≤1.0% NaH2PO4
57-61% water (Karl Fischer)

loss

57-61% loss on drying

pH

8.4-9.6 (20 °C, 1%)

anion traces

chloride (Cl-): ≤10 mg/kg
fluoride (F-): ≤10 mg/kg
sulfate (SO42-): ≤100 mg/kg

cation traces

As: ≤1 mg/kg
Cd: ≤1 mg/kg
Cu: ≤20 mg/kg
Fe: ≤10 mg/kg
Hg: ≤1 mg/kg
K: ≤50 mg/kg
Pb: ≤4 mg/kg
Zn: ≤10 mg/kg

suitability

complies for appearance of solution

SMILES string

O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O

InChI

1S/2Na.H3O4P.12H2O/c;;1-5(2,3)4;;;;;;;;;;;;/h;;(H3,1,2,3,4);12*1H2/q2*+1;;;;;;;;;;;;;/p-2

InChI key

DGLRDKLJZLEJCY-UHFFFAOYSA-L

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Application


  • Study of the Influence of Alkalizing Components on Matrix Pellets Prepared by Extrusion/Spheronization: This publication examines the effects of sodium phosphate dibasic dodecahydrate as an alkalizing agent in matrix pellets, showcasing its application in improving the physicochemical properties of pellets, which are crucial for controlled drug delivery systems (Hamedelniel EI, Bajdik J, Kasa P Jr, Pintye-Hodi K, 2012).

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young
Luciano Candilio et al.
Heart (British Cardiac Society), 101(3), 185-192 (2014-09-26)
Remote ischaemic preconditioning (RIPC), using brief cycles of limb ischaemia/reperfusion, is a non-invasive, low-cost intervention that may reduce perioperative myocardial injury (PMI) in patients undergoing cardiac surgery. We investigated whether RIPC can also improve short-term clinical outcomes. One hundred and
Matthew H Crouthamel et al.
Arteriosclerosis, thrombosis, and vascular biology, 33(11), 2625-2632 (2013-08-24)
Elevated serum phosphate has emerged as a major risk factor for vascular calcification. The sodium-dependent phosphate cotransporter, PiT-1, was previously shown to be required for phosphate-induced osteogenic differentiation and calcification of cultured human vascular smooth muscle cells (VSMCs), but its
Karen Sliwa et al.
Heart (British Cardiac Society), 100(24), 1967-1974 (2014-09-18)
Lack of evidence-based data on the spectrum of cardiovascular disease (CVD) in pregnancy or in the postpartum period, as well as on maternal and fetal outcome, provides challenges for treating physicians, particularly in areas of low resources. The objectives of
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico